J. Balmaña Et Al. , "Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY," Breast Cancer Research and Treatment , vol.204, no.2, pp.237-248, 2024
Balmaña, J. Et Al. 2024. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast Cancer Research and Treatment , vol.204, no.2 , 237-248.
Balmaña, J., Fasching, P. A., Couch, F. J., Delaloge, S., Labidi-Galy, I., O’Shaughnessy, J., ... Park, Y. H.(2024). Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. Breast Cancer Research and Treatment , vol.204, no.2, 237-248.
Balmaña, Judith Et Al. "Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY," Breast Cancer Research and Treatment , vol.204, no.2, 237-248, 2024
Balmaña, Judith Et Al. "Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY." Breast Cancer Research and Treatment , vol.204, no.2, pp.237-248, 2024
Balmaña, J. Et Al. (2024) . "Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY." Breast Cancer Research and Treatment , vol.204, no.2, pp.237-248.
@article{article, author={Judith Balmaña Et Al. }, title={Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY}, journal={Breast Cancer Research and Treatment}, year=2024, pages={237-248} }